Guggenheim raised the firm’s price target on Regeneron (REGN) to $975 from $865 and keeps a Buy rating on the shares. The firm, which updated its model after earnings, sees key upcoming catalysts that include the fianlimab/Libtayo LAG-3 data in melanoma due in the first half, an FDA decision for the Eylea HD pre-filled syringe in Q2, and an NDA submission for cemdisiran in generalized myasthenia gravis in Q1.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Regeneron Targets Early Myeloma: New Phase 3 Trial Pits Linvoseltamab Against Daratumumab
- Regeneron’s REGN9533 Trial Completion Signals Quiet but Important Progress in Clot-Blocking Drugs
- Regeneron’s Expanding AI Use Raises Data Privacy, Regulatory and Market Risks
- Regeneron Broadens Women’s Health Pipeline With New Phase 2 FHA Trial
- Regeneron price target raised to $800 from $740 at Cantor Fitzgerald